カテゴリ： Allied Market Research, 世界, 医療/バイオ

ジェネリック医薬品のグローバル市場（2023-2032）：心血管、感染症、がん、糖尿病、その他

■ 英語タイトル：Generic Drugs Market By Therapeutic Application (Cardiovascular, Infectious Diseases, Cancer, Diabetes, Others), By Route of Administration (Oral, Injections, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP154）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP154
■ 発行日：2023年6月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：252
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ジェネリック医薬品のグローバル市場（2023-2032）：心血管、感染症、がん、糖尿病、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ジェネリック医薬品市場は、2022年に3,853億2,000万ドルと評価され、2023年から2032年までの年平均成長率は8.1%で、2032年には8,357億650万ドルに達すると予測されています。ジェネリック医薬品は、先発医薬品に類似した医薬品で、用量、効能、投与方法、品質、性能特性、使用目的などの点で先発医薬品の承認を受けたものです。ジェネリック医薬品は、先発医薬品に比べて低価格で入手できます。

ジェネリック医薬品市場の成長を牽引しているのは、糖尿病、癌、心血管疾患などの慢性疾患の急増です。世界がん研究基金インターナショナル（WCRF）によると、2020年の世界のがん患者数は推定1,810万人で、そのうち男性が930万人、女性が880万人です。また、ジェネリック医薬品の手頃な価格や最新の製品承認・上市が市場の成長に寄与しています。例えば、2021年2月、研究主導型のグローバル総合製薬企業であるグレンマーク・ファーマシューティカルズは、腎臓がん治療薬スニチニブ経口カプセルのジェネリック医薬品であるSUTIBをインドで発売すると発表しました。
さらに、ブランド薬の価格上昇、ジェネリック医薬品に対する高い需要、ジェネリック医薬品に対する意識の高まりが市場の成長に寄与しています。さらに、世界のジェネリック医薬品市場の有力企業は、市場での地位を強化し、競争状況を維持するために、製品の発売、買収、ジェネリック医薬品の進歩のための研究開発への投資など、さまざまな戦略を採用しています。

さらに、糖尿病有病率の憂慮すべき増加、ジェネリック医薬品の技術的進歩、老人人口の増加は、市場の成長を促進する主な要因の一部です。老年人口は糖尿病や高血圧などの慢性疾患にかかりやすい傾向にあります。しかし、ジェネリック医薬品の一貫性や安定性に関する懸念が市場成長の妨げとなっています。逆に、国民のジェネリック医薬品に対する意識の高まりは、近い将来、市場成長に有利な機会をもたらすと期待されています。また、医療インフラの大幅な改善とともに、ジェネリック医薬品分野における広範な研究開発活動は、予測期間中に市場拡大の新たな道を開くと予想されます。

ジェネリック医薬品市場は、治療用途、投与経路、流通チャネル、地域に区分されます。治療用途ベースでは、市場は心血管、感染症、癌、糖尿病、その他に分けられます。投与経路に基づくと、市場は経口剤、注射剤、その他に分類されます。

流通チャネルでは、病院薬局、小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）で調査しています。
本レポートに掲載されている主要企業には、Amneal Pharmaceuticals、Aurobindo Pharma、Cipla、GlaxoSmithKline Plc、Hikma Pharmaceuticals、Lupin Pharmaceuticals、Sandoz International GmbH、Sun Pharmaceuticals、Teva Pharmaceutical Industries Ltd.、Viatris Inc.などがあります。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までのジェネリック医薬品市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、ジェネリック医薬品市場の市場機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
ジェネリック医薬品市場のセグメンテーションを詳細に分析し、市場機会を把握します。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別、世界別のジェネリック医薬品市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
流通チャネル別
病院薬局
小売薬局
オンラインプロバイダー

治療用途別
循環器
感染症
がん
糖尿病
その他

投与経路別
経口剤
注射
その他

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
中国
日本
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Amneal Pharmaceuticals, Inc.
○ Aurobindo Pharma
○ Cipla Ltd
○ GlaxoSmithKline plc
○ Hikma Pharmaceuticals PLC
○ Lupin
○ Novartis AG
○ Sun Pharmaceutical Industries Ltd
○ Teva Pharmaceutical Industries Limited
○ Viatris Inc.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：ジェネリック医薬品市場、治療用途別
第5章：ジェネリック医薬品市場、投与経路別
第6章：ジェネリック医薬品市場、流通チャネル別
第7章：ジェネリック医薬品市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic diseases
3.4.1.2. Availability of low-cost generic drugs
3.4.1.3. Upsurge in geriatric population

3.4.2. Restraints
3.4.2.1. Concern related to the quality of generic drugs

3.4.3. Opportunities
3.4.3.1. Patent expiry of branded drugs and new product approvals

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Cardiovascular
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Infectious Diseases
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Cancer
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Diabetes
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injections
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: GENERIC DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Therapeutic Application
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Therapeutic Application
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Therapeutic Application
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Therapeutic Application
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Therapeutic Application
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Therapeutic Application
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Therapeutic Application
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Therapeutic Application
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Therapeutic Application
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Therapeutic Application
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Therapeutic Application
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Therapeutic Application
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Therapeutic Application
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Therapeutic Application
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Therapeutic Application
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Therapeutic Application
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Therapeutic Application
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Therapeutic Application
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Therapeutic Application
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Therapeutic Application
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Therapeutic Application
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Therapeutic Application
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Therapeutic Application
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Amneal Pharmaceuticals, Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. GlaxoSmithKline plc
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Teva Pharmaceutical Industries Limited
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Viatris Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Sun Pharmaceutical Industries Ltd
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Cipla Ltd
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Hikma Pharmaceuticals PLC
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Lupin
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Aurobindo Pharma
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 02. GENERIC DRUGS MARKET FOR CARDIOVASCULAR, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GENERIC DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GENERIC DRUGS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GENERIC DRUGS MARKET FOR DIABETES, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 08. GENERIC DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GENERIC DRUGS MARKET FOR INJECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 12. GENERIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GENERIC DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GENERIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 21. U.S. GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 22. U.S. GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. CANADA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 24. CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 25. CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. MEXICO GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 27. MEXICO GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 28. MEXICO GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 30. EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. EUROPE GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 34. GERMANY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. GERMANY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. FRANCE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 37. FRANCE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 38. FRANCE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. UK GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 40. UK GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 41. UK GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. ITALY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 43. ITALY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. ITALY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. SPAIN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 46. SPAIN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 47. SPAIN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. CHINA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 56. CHINA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 57. CHINA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. JAPAN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 59. JAPAN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. JAPAN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. INDIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 62. INDIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 63. INDIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 74. LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. LAMEA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 78. BRAZIL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. BRAZIL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. AMNEAL PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 90. AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 91. AMNEAL PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 92. AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 93. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 94. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 95. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 96. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS AG: KEY EXECUTIVES
TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 105. VIATRIS INC.: KEY EXECUTIVES
TABLE 106. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 107. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 108. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 109. VIATRIS INC.: KEY STRATERGIES
TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 114. CIPLA LTD: KEY EXECUTIVES
TABLE 115. CIPLA LTD: COMPANY SNAPSHOT
TABLE 116. CIPLA LTD: PRODUCT SEGMENTS
TABLE 117. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 118. HIKMA PHARMACEUTICALS PLC: KEY EXECUTIVES
TABLE 119. HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 120. HIKMA PHARMACEUTICALS PLC: PRODUCT SEGMENTS
TABLE 121. HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 122. LUPIN: KEY EXECUTIVES
TABLE 123. LUPIN: COMPANY SNAPSHOT
TABLE 124. LUPIN: PRODUCT SEGMENTS
TABLE 125. LUPIN: PRODUCT PORTFOLIO
TABLE 126. LUPIN: KEY STRATERGIES
TABLE 127. AUROBINDO PHARMA: KEY EXECUTIVES
TABLE 128. AUROBINDO PHARMA: COMPANY SNAPSHOT
TABLE 129. AUROBINDO PHARMA: PRODUCT SEGMENTS
TABLE 130. AUROBINDO PHARMA: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 血栓溶解薬のグローバル市場（2023-2032）：血栓溶解薬、抗血小板薬、抗凝固薬、その他
  • 神経芽腫治療薬のグローバル市場（2023-2032）：化学療法、免疫療法、その他
  • 医薬品ドラッグデリバリーのグローバル市場（2023-2032）：経口ドラッグデリバリー、経鼻ドラッグデリバリー、眼球ドラッグデリバリー、局所ドラッグデリバリー、その他
  • 抗肥満薬のグローバル市場（2023-2032）：処方薬、市販薬
  • インクレチン系薬剤のグローバル市場（2023-2032）：GLP-1受容体作動薬、DPP-4阻害薬
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP154 )"ジェネリック医薬品のグローバル市場（2023-2032）：心血管、感染症、がん、糖尿病、その他" (英文：Generic Drugs Market By Therapeutic Application (Cardiovascular, Infectious Diseases, Cancer, Diabetes, Others), By Route of Administration (Oral, Injections, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。